Immutep Limited
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more
Immutep Limited (PRRUF) - Net Assets
Latest net assets as of June 2025: $143.64 Million USD
Based on the latest financial reports, Immutep Limited (PRRUF) has net assets worth $143.64 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($156.98 Million) and total liabilities ($13.35 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $143.64 Million |
| % of Total Assets | 91.5% |
| Annual Growth Rate | 26.52% |
| 5-Year Change | 96.03% |
| 10-Year Change | 306.7% |
| Growth Volatility | 199.28 |
Immutep Limited - Net Assets Trend (2008–2025)
This chart illustrates how Immutep Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Immutep Limited (2008–2025)
The table below shows the annual net assets of Immutep Limited from 2008 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $143.64 Million | -24.21% |
| 2024-06-30 | $189.52 Million | +38.87% |
| 2023-06-30 | $136.47 Million | +45.06% |
| 2022-06-30 | $94.08 Million | +28.40% |
| 2021-06-30 | $73.27 Million | +120.04% |
| 2020-06-30 | $33.30 Million | +36.54% |
| 2019-06-30 | $24.39 Million | -27.25% |
| 2018-06-30 | $33.52 Million | +26.34% |
| 2017-06-30 | $26.53 Million | -24.87% |
| 2016-06-30 | $35.32 Million | +43.05% |
| 2015-06-30 | $24.69 Million | +9.28% |
| 2014-06-30 | $22.59 Million | -22.76% |
| 2013-06-30 | $29.25 Million | -21.29% |
| 2012-06-30 | $37.16 Million | -32.56% |
| 2011-06-30 | $55.10 Million | +228.21% |
| 2010-06-30 | $16.79 Million | +826.20% |
| 2009-06-30 | $1.81 Million | -31.17% |
| 2008-06-30 | $2.63 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Immutep Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 40822932400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $535.07 Million | 372.52% |
| Other Comprehensive Income | $52.65 Million | 36.65% |
| Other Components | $1.00 | 0.00% |
| Total Equity | $143.64 Million | 100.00% |
Immutep Limited Competitors by Market Cap
The table below lists competitors of Immutep Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen MinDe Electronics Technology Ltd
SHE:300656
|
$244.43 Million |
|
Genfit S.A.
NASDAQ:GNFT
|
$244.43 Million |
|
Mills Estruturas e Serviços de Engenharia S.A
SA:MILS3
|
$244.55 Million |
|
Linzhou Heavy Machinery Group Co Ltd
SHE:002535
|
$244.58 Million |
|
Wuhan Sante Cableway Group Co Ltd
SHE:002159
|
$244.39 Million |
|
Hanson International Tbk
JK:MYRX
|
$244.37 Million |
|
Sanyou Corporation Limited
SHE:300932
|
$244.36 Million |
|
Liaoning SG Automotive Group Co Ltd
SHG:600303
|
$244.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Immutep Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 189,521,742 to 143,635,363, a change of -45,886,379 (-24.2%).
- Net loss of 61,434,165 reduced equity.
- Other comprehensive income increased equity by 22,583,096.
- Other factors decreased equity by 7,035,310.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-61.43 Million | -42.77% |
| Other Comprehensive Income | $22.58 Million | +15.72% |
| Other Changes | $-7.04 Million | -4.9% |
| Total Change | $- | -24.21% |
Book Value vs Market Value Analysis
This analysis compares Immutep Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.03x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.35x to 2.03x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-06-30 | $0.09 | $0.20 | x |
| 2009-06-30 | $0.05 | $0.20 | x |
| 2010-06-30 | $0.28 | $0.20 | x |
| 2011-06-30 | $0.96 | $0.20 | x |
| 2012-06-30 | $0.35 | $0.20 | x |
| 2013-06-30 | $0.27 | $0.20 | x |
| 2014-06-30 | $0.18 | $0.20 | x |
| 2015-06-30 | $0.15 | $0.20 | x |
| 2016-06-30 | $0.15 | $0.20 | x |
| 2017-06-30 | $0.13 | $0.20 | x |
| 2018-06-30 | $0.13 | $0.20 | x |
| 2019-06-30 | $0.07 | $0.20 | x |
| 2020-06-30 | $0.08 | $0.20 | x |
| 2021-06-30 | $0.12 | $0.20 | x |
| 2022-06-30 | $0.11 | $0.20 | x |
| 2023-06-30 | $0.15 | $0.20 | x |
| 2024-06-30 | $0.16 | $0.20 | x |
| 2025-06-30 | $0.10 | $0.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Immutep Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -42.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1218.02%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.09x
- Recent ROE (-42.77%) is above the historical average (-65.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -71.67% | 0.00% | 0.00x | 1.07x | $-2.15 Million |
| 2009 | -162.53% | 0.00% | 0.00x | 1.37x | $-3.13 Million |
| 2010 | -72.43% | -2321.57% | 0.03x | 1.13x | $-13.84 Million |
| 2011 | -38.26% | 0.00% | 0.00x | 1.05x | $-26.59 Million |
| 2012 | -53.67% | -1311.89% | 0.04x | 1.12x | $-23.66 Million |
| 2013 | -52.06% | -496.54% | 0.09x | 1.12x | $-18.15 Million |
| 2014 | -59.06% | -549.84% | 0.10x | 1.12x | $-15.60 Million |
| 2015 | -130.22% | -1715.89% | 0.06x | 1.25x | $-34.62 Million |
| 2016 | -175.59% | -35426.72% | 0.00x | 1.20x | $-65.55 Million |
| 2017 | -35.30% | -227.54% | 0.12x | 1.32x | $-12.02 Million |
| 2018 | -38.02% | -484.55% | 0.06x | 1.40x | $-16.10 Million |
| 2019 | -75.22% | -13123.28% | 0.00x | 1.66x | $-20.78 Million |
| 2020 | -40.45% | -179.90% | 0.16x | 1.40x | $-16.80 Million |
| 2021 | -40.81% | -24929.03% | 0.00x | 1.12x | $-37.23 Million |
| 2022 | -34.24% | -18906.51% | 0.00x | 1.09x | $-41.62 Million |
| 2023 | -29.23% | -1138.04% | 0.02x | 1.08x | $-53.54 Million |
| 2024 | -22.54% | -1111.87% | 0.02x | 1.06x | $-61.67 Million |
| 2025 | -42.77% | -1218.02% | 0.03x | 1.09x | $-75.80 Million |
Industry Comparison
This section compares Immutep Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Immutep Limited (PRRUF) | $143.64 Million | -71.67% | 0.09x | $244.42 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |